Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2012 Publisher: Aventis Pharma S.A. 20 avenue Raymond Aron 92165 Antony Cedex France
TAXOTERE 20 mg/1 ml concentrate for solution for infusion.
| Pharmaceutical Form |
|---|
|
Concentrate for solution for infusion (sterile concentrate). The concentrate is a pale yellow to brownish-yellow solution. |
Each ml of concentrate contains 20 mg docetaxel (as trihydrate).
One vial of 1 ml of concentrate contains 20 mg of docetaxel.
Excipient with known effect: Each vial of concentrate contains 0.5 ml of ethanol anhydrous (395 mg).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Docetaxel |
Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. |
| List of Excipients |
|---|
|
Polysorbate 80 |
7 ml clear glass (type I) vial with a green aluminium seal and a green plastic flip-off cap containing 1 ml of concentrate.
Each box contains one vial.
Not all pack sizes may be marketed.
Aventis Pharma S.A.
20 avenue Raymond Aron
92165 Antony Cedex
France
EU/1/95/002/003
Date of first authorisation: 27 November 1995
Date of latest renewal: 27 November 2005
| Drug | Countries | |
|---|---|---|
| TAXOTERE | Austria, Brazil, Cyprus, Ecuador, Estonia, Spain, France, Hong Kong, Ireland, Japan, Lithuania, Mexico, Nigeria, Netherlands, Poland, Tunisia, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
